Liver and biliary tract cancer: who works on it

One card per institution. Pick a target or a country to narrow the list.

• All targets
• PD-1 91
• PD-L1 51
• TP53 3
• PI3K 0
• mTOR 1
• AKT 0
• STAT3 1
• VEGF 20
• FGFR 22
• GPC3 38
• CTNNB1 5
• YAP 0
• MAPK 0
• HER2 28
• NRF2 0
• HIF-1 0
• PPAR 0
• ERK 0
• AMPK 0
• STING 0
• EGFR 8
• CTLA-4 19
• MYC 0
• IDH 6
• JAK 0
• JNK 0
• PTEN 0
• GPX4 0
• KRAS 8
• BCL-2 0
• HSP90 0
• IL-6 1
• PSMA 8
• MET 1
• GLP-1 1
• BRAF 3
• EZH2 0
• NLRP3 0
• CLDN18 10
• MEK 0
• B7-H3 5
• COX-2 0
• HDAC 0
• CXCR4 0
• HMGB1 0
• METTL3 0
• SIRT1 0
• TLR4 0
• MMP-9 0
• TNF 0
• PARP 2
• PCSK9 0
• TIGIT 2
• TIM-3 1
• IL-17 0
• RAS 2
• SGLT2 0
• CD47 0
• CDK4/6 0
• IL-15 2

24 of 28+ institutions, ordered by recent publications and open trials. This is not a ranking of quality.

Funded research projects that name this disease in their title, terms or summary and have not ended yet: who is funded, where, how much and until when. Organisations only; the funder's page has the details.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  Glutaminase Isoenzymes: Gatekeepers of Bioenergetics, Immunity, and Tumor Microenvironment in Diabetes-Induced Hepatocellular Carcinoma (IRM)

  Fundacion Para la Investigacion de Malaga En Biomedicina y Salud· Malaga, Spain· EU contribution €209,915· until Aug 2029

• European Commission (Horizon Europe) · HORIZON-ERC

  Decoding Neural Circuits in Cholangiocarcinoma (LIVER-CIRCUITS)

  Technische Universitaet Dresden· Dresden, Germany· EU contribution €1,500,000· until Dec 2031

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  Unravelling Malignant Cholangiocyte Subpopulations that Drive Chemoresistance in Cholangiocarcinoma (RESIST-CCA)

  Humanitas Mirasole Spa· Rozzano (Mi), Italy· EU contribution €193,643· until Dec 2028

• European Commission (Horizon Europe) · HORIZON-ERC-POC

  Multiscale 3D virtual histology with non-destructive x-rays (XHIST)

  Danmarks Tekniske Universitet· Kongens Lyngby, Denmark· EU contribution €150,000· until Mar 2028

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-ERC

  Mechano-metabOlic Responsive nanoPlatform for HeterogEnous tUmor Suppression (MORPHEUS)

  Fundacion de la Comunidad Valenciana Centro de Investigacion Principe Felipe· Valencia, Spain· EU contribution €2,499,745· until Aug 2031

  The disease is named only in the funder's project summary, not in the title.

5 of 39 running projects, newest first. Listed amounts together: €133.0m.

Sources: NIH RePORTER (U.S. National Institutes of Health, public domain) and CORDIS (European Commission, CC BY 4.0). Changes: filtered by disease, organisations matched to ROR.

Terminated, withdrawn and suspended trials with the reason the sponsor gave in the registry, quoted word for word.

• Suspended

  Autologous CAR T Cells Targeting GPC3 (RPCAR01) for the Treatment of Advanced or Metastatic GPC3 Expressing Hepatocellular Carcinoma

  NCT06968195· Roswell Park Cancer Institute· Updated 15 Sept 2026

  “awaiting agreement with Sponsor”Registry text, quoted unchanged. Source

• Terminated

  GPC3-targeting CART Cell in Treatment of Advanced Hepatocellular Carcinoma

  NCT05352542· jianming xu· Updated 9 Aug 2024

  “achieve the proof of concept”Registry text, quoted unchanged. Source

• Withdrawn

  T Cells co- Expressing a Second Generation Glypican 3-specific Chimeric Antigen Receptor With Cytokines Interleukin-21 and 15 as Immunotherapy for Patients With Liver Cancer (TEGAR)

  NCT04093648· Baylor College of Medicine· Updated 20 May 2020

  “The key elements of this study were incorporated into another study.”Registry text, quoted unchanged. Source

Trials whose registry record says individual participant data (IPD) will be shared.

• Study Evaluating the Efficacy and Safety of BGB-B2033 in Participants With Advanced Hepatocellular Carcinoma

  NCT07911683· BeOne Medicines· Source

• 68Ga-NYM207 PET/CT Imaging in Hepatocellular Carcinoma

  NCT07590336· Peking Union Medical College Hospital· Source

• GPC3 Targeted CAR-T Cell Therapy in Advanced GPC3 Expressing Solid Tumor Malignancies

  NCT05003895· National Cancer Institute (NCI)· Source

• First in Human Study to Evaluate AZD9793 in Participants With Advanced or Metastatic Solid Tumours

  NCT06795022· AstraZeneca· Source

• A Phase 1/2 Study of BGB-B2033, Alone or in Combination With Tislelizumab With or Without Bevacizumab, in Participants With Advanced or Metastatic Solid Tumors

  NCT06427941· BeOne Medicines· Source

• A Phase I/II Study to Evaluate AZD5851 in GPC3+ Advanced/Recurrent Hepatocellular Carcinoma

  NCT06084884· AstraZeneca· Source

Find publications on this disease by a MeSH method term, for example a sequencing or imaging method.

• Single-Cell Analysis 109
• Organoids 40
• Mendelian Randomization Analysis 38
• CRISPR-Cas Systems 34
• Gene Expression Profiling 281
• Sequence Analysis, RNA 20
• Whole Genome Sequencing 9
• Exome Sequencing 19
• Proteomics 119
• Metabolomics 73
• Mass Spectrometry 23
• Flow Cytometry 66
• Immunohistochemistry 125
• Liquid Biopsy 34
• Circulating Tumor DNA 41
• Xenograft Model Antitumor Assays 443
• Positron-Emission Tomography 35
• Magnetic Resonance Imaging 376
• Machine Learning 198
• Deep Learning 114
• Cohort Studies 184
• Genome-Wide Association Study 42

• Integrative Multi-Omics Mendelian Randomization Analysis Identifies NIT2 as a Potential Metabolic Risk Gene in Hepatocellular Carcinoma.

  J Gene Med, Sept 2026

• Mendelian Randomization Using a Japanese GWAS Identifies an HLA-Linked Causal Effect of Chronic Hepatitis B on Cholangiocarcinoma Risk.

  Asian Pac J Cancer Prev, Aug 2026

• Mendelian Randomization and Single-Cell Transcriptomic Analyses Implicate PPP1R1B as a Risk Factor of Intrahepatic Cholangiocarcinoma.

  Genes (Basel), Jul 2026

• Causal association between oral microbiota and hepatocellular carcinoma in East Asian populations: a Mendelian randomization study.

  Nan Fang Yi Ke Da Xue Xue Bao, Jul 2026

• Identification of therapeutic targets and postoperative recurrence prediction model construction for hepatocellular carcinoma based on systematic mendelian randomization.

  Arab J Gastroenterol, Jul 2026

• New-Onset Type 2 Diabetes Mellitus and Cancer Risk: A Matched Cohort Study in China Kadoorie Biobank.

  Int J Cancer, Jul 2026

• Causal effects of blood and urinary biomarkers on cancer risk: A Mendelian randomization study.

  J Int Med Res, Jul 2026

• Causal effects of cholelithiasis on hepatopancreatobiliary diseases: a multi-cohort Mendelian randomization study.

  BMC Gastroenterol, Jun 2026

• Mechanistic insights into Tuoli Xiaozheng Formula for hepatocellular carcinoma: An integrated network pharmacology, molecular docking, and Mendelian randomization analysis.

  Medicine (Baltimore), Jun 2026

• Mendelian randomization analysis of metabolic blood biomarkers and gastrointestinal cancer risk.

  Adv Clin Exp Med, Jun 2026

See which targets of this disease your abstract mentions, and go to the people working on them.